Would it then be correct to assume that DCVAX-L has a greater benefit than current SOC, if the results of the trials used to establish that SOC were to be re-calculated (if possible) based on this revised definition of GBM? So, the previously stated PFS of 19.4 months for the Stupp protocol could actually be lower.
Market Data 
Markets 
AI
